Janssen Adds Yuhan’s Lazertinib to its Oncology Pipeline in a US$1.25 B Deal
By Jawala Prasad & Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 20 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2372 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Just a few weeks after ending four oncology deals worth at least US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS